Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (686)	5/9/2006 2:42:37 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 933

Little flurry of activity in the trading past hour. Kosan may be as good as anything for ASCO. kosan.com Kosan will present data from two Phase Ib clinical trials of its lead heat shock protein 90 (Hsp90) inhibitor product candidate, KOS-953, administered in combination with trastuzumab (Herceptin®) in patients with metastatic breast cancer, and with bortezomib (Velcade®) in patients with relapsed refractory multiple myeloma. The company will also present Phase I single-agent clinical trial results of intravenous KOS-1022, a second-generation Hsp90 inhibitor, in patients with advanced hematological malignancies. In its epothilone program, Kosan and its partner Roche will also present clinical data on KOS-862, the companies’ most advanced epothilone drug candidate, administered in combination with Herceptin in HER-2 positive metastatic breast cancer. In addition, data will be reported from two Phase I clinical trials of KOS-1584, a novel “fast-follower” epothilone product candidate with different pharmacokinetic properties than KOS-862 that may result in an improved safety and efficacy profile.